Skye Bioscience Acquires Redx Pharma, Exits Obesity for Fibrosis Focus

Skye Bioscience has acquired Redx Pharma and shifted its focus from obesity to fibrosis and oncology, rebranding as Fibrx Therapeutics and raising approximately $125 million to fund development, including a Phase 2 trial for fibrostenotic Crohn’s disease.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.